◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

LONGBIO-B (1779) Financial History

Name: LONGBIO-B (1779) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

LONGBIO-B (1779) operates in the Biotechnology industry and is headquartered in Changshu, China with about 85 employees. Its market capitalization is roughly CNY 10 billion. In the fiscal year ended 2025-12-31, 1779 reported CNY 0M in revenue and (CNY 176M) in net income.

LongBio Pharma (Suzhou) Co., Ltd. engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong.

Interactive charts & full statements →

1779 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31
Total Revenue	CNY 0M	CNY 0M
Operating Income (EBIT)	(CNY 159M)	(CNY 108M)
Net Income	(CNY 176M)	(CNY 137M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1779 Free Cash Flow History

1779 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31
Total Assets	CNY 228M	CNY 149M
Total Liabilities	CNY 87M	CNY 479M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1779 viewer.

Other Companies in Biotechnology

4875 · MediciNova, Inc. — $10 billion
2493 · MABWELL-B — $10 billion
6872 · TENNOR THERAP-B — $10 billion
NUVL · Nuvalent Inc — $10 billion
ABVX · ABIVAX Société Anonyme — $9 billion
6938 · Suzhou Ribo Life Science Co — $9 billion
2171 · CARsgen Therapeutics Holdings Limited — $9 billion
2616 · CStone Pharmaceuticals — $8 billion

← 1778 All “0-9” companies 1780 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.